{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T05:18:02Z","timestamp":1775279882419,"version":"3.50.1"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medical Hypotheses"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.mehy.2019.109241","type":"journal-article","created":{"date-parts":[[2019,5,20]],"date-time":"2019-05-20T15:24:13Z","timestamp":1558365853000},"page":"109241","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["CD133 receptor mediated delivery of STAT3 inhibitor for simultaneous elimination of cancer cells and cancer stem cells in oral squamous cell carcinoma"],"prefix":"10.1016","volume":"129","author":[{"given":"Sai Harshini","family":"Pindiprolu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sai Kiran S.S.","family":"Pindiprolu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.mehy.2019.109241_b0005","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1200\/JCO.2007.14.1713","article-title":"Incidence trends for human papillomavirus-related and-unrelated oral squamous cell carcinomas in the United States","volume":"26","author":"Chaturvedi","year":"2008","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.mehy.2019.109241_b0010","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/onc.2012.85","article-title":"CD133+ cells with cancer stem cell characteristics associates with vasculogenic mimicry in triple-negative breast cancer","volume":"32","author":"Liu","year":"2013","journal-title":"Oncogene"},{"issue":"7","key":"10.1016\/j.mehy.2019.109241_b0015","doi-asserted-by":"crossref","first-page":"3983","DOI":"10.1073\/pnas.0530291100","article-title":"Prospective identification of tumorigenic breast cancer cells","volume":"100","author":"Al-Hajj","year":"2003","journal-title":"Proc Natl Acad Sci"},{"issue":"3","key":"10.1016\/j.mehy.2019.109241_b0020","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1073\/pnas.0610117104","article-title":"Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma","volume":"104","author":"Prince","year":"2007","journal-title":"Proc Natl Acad Sci"},{"issue":"4","key":"10.1016\/j.mehy.2019.109241_b0025","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.biocel.2011.12.020","article-title":"Breast cancer stem cells","volume":"44","author":"Velasco-Vel\u00e1zquez","year":"2012","journal-title":"Int J Biochem Cell Biol"},{"issue":"34","key":"10.1016\/j.mehy.2019.109241_b0030","doi-asserted-by":"crossref","first-page":"4741","DOI":"10.1038\/onc.2010.215","article-title":"EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer","volume":"29","author":"Singh","year":"2010","journal-title":"Oncogene"},{"issue":"10","key":"10.1016\/j.mehy.2019.109241_b0035","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.oraloncology.2012.05.011","article-title":"Epithelial to mesenchymal transition (EMT) biomarkers\u2013E-cadherin, beta-catenin, APC and Vimentin\u2013in oral squamous cell carcinogenesis and transformation","volume":"48","author":"Chaw","year":"2012","journal-title":"Oral Oncol"},{"issue":"6","key":"10.1016\/j.mehy.2019.109241_b0040","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1093\/jb\/mvr044","article-title":"Cancer early dissemination: cancerous epithelial\u2013mesenchymal transdifferentiation and transforming growth factor \u03b2 signalling","volume":"149","author":"Sabe","year":"2011","journal-title":"J Biochem"},{"issue":"4","key":"10.1016\/j.mehy.2019.109241_b0045","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.cell.2011.07.026","article-title":"Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells","volume":"146","author":"Gupta","year":"2011","journal-title":"Cell"},{"issue":"29","key":"10.1016\/j.mehy.2019.109241_b0050","doi-asserted-by":"crossref","first-page":"7191","DOI":"10.1016\/j.biomaterials.2013.06.004","article-title":"Targeted delivery of miR-200c\/DOC to inhibit cancer stem cells and cancer cells by the gelatinases-stimuli nanoparticles","volume":"34","author":"Liu","year":"2013","journal-title":"Biomaterials"},{"issue":"4\/5","key":"10.1016\/j.mehy.2019.109241_b0055","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.oraloncology.2009.01.004","article-title":"Oral squamous cell carcinoma overview","volume":"45","author":"Scully","year":"2009","journal-title":"Oral Oncol"},{"issue":"19","key":"10.1016\/j.mehy.2019.109241_b0060","doi-asserted-by":"crossref","first-page":"9339","DOI":"10.1158\/0008-5472.CAN-06-3126","article-title":"Cancer stem cells\u2014perspectives on current status and future directions: AACR Workshop on cancer stem cells","volume":"66","author":"Clarke","year":"2006","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.mehy.2019.109241_b0065","doi-asserted-by":"crossref","first-page":"303","DOI":"10.4048\/jbc.2015.18.4.303","article-title":"New findings on breast cancer stem cells: a review","volume":"18","author":"Bozorgi","year":"2015","journal-title":"J Breast Cancer"},{"key":"10.1016\/j.mehy.2019.109241_b0070","doi-asserted-by":"crossref","DOI":"10.1080\/21691401.2017.1366337","article-title":"Nanocarrier based approaches for targeting breast cancer stem cells","author":"Pindiprolu","year":"2018","journal-title":"Artif Cells Nanomed Biotechnol"},{"issue":"2","key":"10.1016\/j.mehy.2019.109241_b0075","doi-asserted-by":"crossref","first-page":"181","DOI":"10.2217\/nnm.13.195","article-title":"Nanomedicine for treatment of cancer stem cells","volume":"9","author":"Gao","year":"2014","journal-title":"Nanomedicine"},{"key":"10.1016\/j.mehy.2019.109241_b0080","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2016.00313","article-title":"Nanomedicine-mediated therapies to target breast cancer stem cells","volume":"7","author":"He","year":"2016","journal-title":"Front Pharmacol"},{"issue":"1","key":"10.1016\/j.mehy.2019.109241_b0085","first-page":"1","article-title":"CD133: a stem cell biomarker and beyond","volume":"2","author":"Li","year":"2013","journal-title":"Experim Hematol Oncol"},{"issue":"1","key":"10.1016\/j.mehy.2019.109241_b0090","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1007\/s11051-013-2157-5","article-title":"Paclitaxel-loaded nanoparticles decorated with anti-CD133 antibody: a targeted therapy for liver cancer stem cells","volume":"16","author":"Jin","year":"2014","journal-title":"J Nanopart Res"},{"issue":"6","key":"10.1016\/j.mehy.2019.109241_b0095","doi-asserted-by":"crossref","first-page":"165","DOI":"10.3390\/toxins8060165","article-title":"CD133, selectively targeting the root of cancer","volume":"8","author":"Schmohl","year":"2016","journal-title":"Toxins"},{"issue":"3","key":"10.1016\/j.mehy.2019.109241_b0100","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jconrel.2013.07.014","article-title":"CD133-targeted paclitaxel delivery inhibits local tumor recurrence in a mouse model of breast cancer","volume":"171","author":"Swaminathan","year":"2013","journal-title":"J Control Release"}],"container-title":["Medical Hypotheses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987719303822?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987719303822?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,29]],"date-time":"2019-07-29T20:01:54Z","timestamp":1564430514000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0306987719303822"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":20,"alternative-id":["S0306987719303822"],"URL":"https:\/\/doi.org\/10.1016\/j.mehy.2019.109241","relation":{},"ISSN":["0306-9877"],"issn-type":[{"value":"0306-9877","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CD133 receptor mediated delivery of STAT3 inhibitor for simultaneous elimination of cancer cells and cancer stem cells in oral squamous cell carcinoma","name":"articletitle","label":"Article Title"},{"value":"Medical Hypotheses","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mehy.2019.109241","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109241"}}